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PURPOSE. We describe the clinical features in two pedigrees with dominantly inherited
retinopathy segregating the previously reported frameshifting mutation, c.836dupG
(p.Ile280Asn*78) in the terminal exon of the RGR gene, and compare their haplotypes to
that of the previously reported pedigree.
METHODS. The probands were ascertained at West Virginia University Eye Institute (WVU) and
Moorfields Eye Hospital (MEH) through next generation sequencing (NGS) and whole
genome sequencing (WGS) respectively. Clinical data included visual acuity (VA), visual fields,
fundus autofluorescence (FAF), optical coherence tomography (OCT), and electroretinogra-
phy (ERG). Haplotype analysis was performed using Sanger sequencing of the DNA from the
molecularly ascertained individuals from the three pedigrees.
RESULTS. Nine heterozygous mutation carriers were identified in two families. Four carriers
were asymptomatic; five carriers had variable VA reduction, visual field constriction, and
experienced difficulty under dim illumination. Fundus examination of the asymptomatic
carriers showed diffuse or reticular pigmentation of the retina; the symptomatic carriers had
chorioretinal atrophy. FAF imaging showed widespread signal loss in advanced retinopathy,
and reticular hyperautofluorescence in mild cases. OCT showed loss of outer retinal lamina in
advanced disease. ERG showed moderate-to-severe rod–cone dysfunction in two symptomatic
carriers; and was normal in three asymptomatic carriers. A shared haplotype flanking the
mutation of up to 6.67 Mb was identified in both families. Within this region, 1.27 Mb were
shared with the first family reported with this retinopathy.
CONCLUSIONS. The clinical data suggest a variable and slow degeneration of the RPE. A shared
chromosomal segment surrounding the RGR gene suggests a single ancestral mutational event
underlying all three families.
Keywords: autosomal dominant retinal dystrophy, deep retinal reticular pigmentation, next
generation sequencing, whole genome sequencing, RGR
Inherited retinal dystrophies are a group of disorders in whichretinal dysfunction and/or degeneration is due to disease-
causing variants in one or both alleles of a single gene. They
present with variable clinical features, and have high genetic
and allelic heterogeneity. To date, disease-causing variants in
more than 300 genes have been identified (available in the
public domain at https://sph.uth.edu/retnet/; The University of
Texas-Houston Health Science Center, Houston, TX, USA).
Proteins encoded by these genes can be expressed ubiquitous-
ly, or by specific retinal cell types.1–4
The retinal G-protein coupled receptor gene (RGR,
MIM_600342) is located on chromosome 10q23.1, and encodes
an intracellular opsin localized to the retinal pigment epithelium
(RPE) and Mu¨ller cells.5–7 To date, only one disease-causing
Copyright 2018 The Authors
iovs.arvojournals.org j ISSN: 1552-5783 4812
This work is licensed under a Creative Commons Attribution 4.0 International License.
Downloaded From: https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/937555/ on 11/08/2018
mutation in RGR has been described: a heterozygous frameshift-
ing mutation (chr10:86018343dupG; NM_002921.3:c.836dupG;
p.Ile280Asn*78 — the same mutation as reported previously),
which was reported in a pedigree with autosomal dominant
retinopathy, but the clinical data were limited (RP44; MIM-
613769).8 An allele reported to be associated with recessive
retinal disease has been re-evaluated, with the disorder in those
patients explained, instead, by biallelic mutation of CDHR1.9
Therefore, the consequences of biallelic loss of function of RGR
on the human retina remain unknown.9 We characterized the
clinical features secondary to the frameshifting mutation
p.Ile280Asn*78 in RGR in two not knowingly related Caucasian
pedigrees from the United Kingdom and United States.
METHODS
Two probands (shown by arrows in Fig. 1) were initially
ascertained through large sequencing studies. Family WVU
was recruited from the medical retina clinic at the West
Virginia University Eye Institute (WVU); family GC4177 was
recruited from the inherited retinal disorders clinic at Moor-
fields Eye Hospital (MEH; Fig. 1). After obtaining informed
consent, the probands and their family members donated
blood for genetic testing. DNA analysis from the WVU family
was performed as part of the National Ophthalmic Disease
Genotyping and Phenotyping Network (eyeGENE) study, as a
Health Insurance Portability and Accountability Act (HIPAA)-
compliant study that was approved by the institutional review
boards at WVU, and the National Eye Institute (Bethesda, MD,
USA). DNA analysis from the GC4177 family was performed as
part of the National Institute for Health Research BioResource -
Rare Diseases (NIHRBR-RD) study, which was approved by
MEH Research Management Ethics, and Cambridge South
Research Committee, and adhered to the tenets of the
Declaration of Helsinki. Details of the molecular investigations
at WVU and MEH, including the haplotype analysis from the
two pedigrees and the family reported by Morimura et al.,8 are
provided in the Supplementary Material.
Sanger sequencing of all coding exons and exon-intron
boundaries of RGR in 18 unrelated probands from MEH, whose
retinal features were similar to those of the MEH proband and
WVU: III-8, and were negative for CHM mutations, did not
identify further carriers of this change or other likely disease-
causing variants in RGR (primers available upon request).
The probands and available family members underwent
ophthalmic examination including best-corrected Snellen
visual acuity (VA), dilated fundus examination, optical coher-
ence tomography (OCT), fundus autofluorescence (FAF)
imaging (Spectralis HRAþOCT; Heidelberg Engineering GmbH,
Heidelberg, Germany), color fundus photography, Goldmann
perimetry, and electrophysiologic testing using protocols that
incorporated the recommendations of the International Society
of Electrophysiology of Vision (ISCEV) for electroretinography
(ERG), pattern electroretinography (PERG), and electrooculog-
raphy (EOG) at the time of examination.10–12
RESULTS
Molecular Genetic Analysis
A previously reported8 heterozygous variant in RGR
(NM_002921.3 c.836dupG; p.Ile280Asnfs*78, MIM_600342.0002)
was detected in the genomic DNA from both probands WVU-
IV:5, and GC4177-IV:1 by targeted next generation sequencing
(NGS) and whole genome sequencing (WGS), respectively.
FIGURE 1. Pedigrees of the families from WVU and MEH-GC4177. Subjects with history of blindness in WVU: I, II, and MEH II, III, and IV are shown
as solid symbols. In both pedigrees, all the genotyped members (denoted as M/WT for heterozygotes and WT/WT for those with wild type alleles)
were examined and retinal images were obtained. Subjects WVU: IV-2, IV-5; and MEH-GC4177: V-2, VI-1 had distinct retinal changes on imaging but
no visual symptoms. Arrows indicate the proband in each family.
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Direct Sanger sequencing of the DNA from available family
members from both pedigrees (Fig. 1; WVU: III-6, III-8, IV-2, IV-
5, IV-6, and GC4177: V-1, V-2, and VI-1) demonstrated the
variant to be present in the DNA from all of these individuals,
and segregate with retinal changes on fundus examination;
WVU: IV-4 had normal ocular examination and the wild type
allele. Haplotype analysis using 32 single nucleotide variants
(SNV), with a minor allele frequency (MAF) of <0.2 in the
gnomAD dataset (available in the public domain at http://gno
mad.broadinstitute.org; Broad Institute, Cambridge, MA, USA),
selected from the WGS data of GC4177: IV-1 showed eight
SNVs to be shared between the following subjects: GC4177: V-
1, V-2 and WVU: IV-5, IV-6 (Table 1), indicating a shared
haplotype region of 6.67 Mb inclusive of RGR (primers
available upon request). Additional Sanger sequencing of the
DNA from three affected and two unaffected family members
from the first pedigree, which was reported by Morimura et
al.,8 for the eight shared SNVs showed a common haplotype of
1.27 Mb across the three pedigrees.
The variant, a duplication of a single nucleotide (G) at
position 836 in exon 7 of RGR, is predicted to result in an out-
of-frame extension through the canonical stop codon, produc-
ing a longer polypeptide with 77 novel amino acid residues at
the C-terminal end, and replacing 16 amino acid residues in the
cytoplasmic domain of RGR. Because the variant is in the
terminal exon of RGR, the transcript is likely to evade
nonsense mediated decay and a mature protein could be
produced.
Clinical Features
The clinical, visual function and imaging data are summarized
in Table 2. Nine subjects were examined, five from two
generations in the WVU pedigree and four from three
generations in the GC4177 pedigree (Fig. 1). No other family
members were available for examination. Median age of the
asymptomatic carriers with normal visual acuity was 50 years
(range, 23–60 years). There was no contributory medical or
drug history.
The earliest symptoms in WVU: III-8 were visual field
defects and reduced VA at the age of 59 years. WVU: III-6 had
visual field defects and mildly reduced VA at the age of 81
years. Subjects GC4177: IV-1 and GC4177: V-1 first noticed
progressive visual field constriction during their third decade
of life. The VA in symptomatic carriers ranged between 20/20
and 20/1000. WVU III-8 had a VA of 20/50 in the right eye and
20/200 improving with pinhole to 20/50 in the left eye at the
age of 77 years, but GC4177: IV-1 suffered severe VA loss
during the seventh decade. Not all subjects were available for
refraction (Table 2). All three carriers from the WVU pedigree
whose visual fields were available showed enlargement of the
blind spot. Additionally, one carrier had bilateral nasal and
temporal scotomata.
Fundus examination of subjects WVU: III-8 and III-6 at ages
77 and 81 years, respectively, and GC4177: IV-1 at age 73 years
showed increased visibility of the large choroidal blood vessels,
in keeping with loss of the RPE, without significant attenuation
of the retinal blood vessels (Figs. 2, 3). Two subjects showed
discrete patches of deep retinal hyperpigmentation: WVU: III-6
(Fig. 2D, green arrow) and GC4177: IV-1 (Fig. 3A, green
arrows). Subject GC4177: V-1 showed only peripapillary
atrophy, but the deep retinal changes became conspicuous
on FAF imaging as described below. The asymptomatic carriers
(WVU: IV-2, IV-5, IV-6 and GC4177: V-2, VI-1) showed, in
addition to peripapillary atrophy, bilateral deep retinal
pigmentation anterior to the vascular arcades (Figs. 2G, 2J)
and nasal to the optic disc (Fig. 3G). Subject GC4177: V-2
showed peripapillary atrophy extending toward the fovea (Fig.
3G).
FAF imaging showed sharply demarcated areas of hypoauto-
fluorescence in advanced cases. The areas of relatively
preserved outer retina had mottling of the AF or reticular
hyperautofluorescence (Figs. 2B, 2E, 3B, 3E). The changes
were more noticeable on FAF than on color fundus imaging,
with FAF showing reticular hyperautofluorescence and patches
of reduced AF (Figs. 2E, 2H, 2K, 3H).
OCT showed marked disruption of the inner segment–outer
segment junction band (IS/OS) in advanced cases (WVU: III-8
and GC4177: IV-1) with attenuation of the outer nuclear layer
(Figs. 2C, 3C). Outer retinal tubulation was present at the
junction between the atrophic fovea and a layer resembling the
IS/OS (Fig. 3C, red arrow) or temporal to the optic nerve head
(Figs. 3I, 3L). Subject WVU: III-6 showed preservation of the
central foveal structure on OCT, separated from the nasal,
atrophic region by a hyporeflective band reminiscent of an
interlaminar bridge (Fig. 2F, yellow arrow). Subject GC4177: V-
1 showed mild IS/OS irregularity on OCT (Fig. 3F, cyan arrow).
The asymptomatic carriers showed attenuation or loss of the
photoreceptor layer in the peripapillary area (Figs. 2I, 2H, 3I).
Foveal lamination was normal in all asymptomatic carriers.
Electroretinography was available for three subjects from
the WVU pedigree—data given in Supplementary Table S1
and waveforms in Figure 4 (one subject also had an EOG)—
and two subjects from the GC4177 pedigree (Fig. 5). The
TABLE 1. Whole Genome Sequencing Data for the Proband GC4177-IV-1
VAR (hg19) rs Number Reference Allele Frequency GC4177 WVU Morimura et al.8
10:81305881 rs149240458 C 0.0001 T T C
10:85446602 rs186897671 C 0.009 T T T
10:85711138 rs61868868 C 0.13 A A A
10:85711734 rs35868777 T 0.14 C C C
10:86018343 .. A NA AG AG AG
10:86713933 rs577984121 A 0.00019 AC AC AC
10:87978214 rs4934162 G 0.047 A A G
10:87979761 rs4934163 T 0.047 C C T
10:90244571 rs750593376 CAG 0.00003 C CAG CAG
Heterozygous for the c.836dupG Mutation in RGR (VAR [hg19] position: 10: 86018343, shown in bold font), were interrogated in the regions>2
Mb telomeric and centromeric to the mutation. All high-quality single-nucleotide polymorphisms (SNPs) with a reference ID in the refSNP cluster
(rs), and an allele frequency of the nonreference allele of <0.2 on gnomAD (available in the public domain at http://gnomad.broadinstitute.org; the
Broad Institute) were identified. DNA from the unaffected father IV-2, and affected children V-1 and V-2 underwent Sanger sequencing of 32 SNPs to
determine the phase relative to the maternally inherited mutation. In eight of these, the phase could be unambiguously determined showing each to
segregate with the RGR mutation. These SNPs were examined by Sanger sequencing in affected members of the other two families. These data
supported a minimal shared haplotype of 1.27 Mb across the three pedigrees (SNPs, shown in italicized font).
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asymptomatic carriers WVU: IV-5 (note the normative data in
Supplementary Table S2) and GC4177: V-2, VI-1 had normal
scotopic and photopic full field ERGs. The PERG was normal
in the youngest carrier GC4177:VI-1, but showed mildly
reduced P50 amplitude in GC4177: V-2. Subjects WVU: III-6
and WVU: III-8 were symptomatic, and the ERG from WVU:
III-6 showed moderately severe reduction of the scotopic
amplitudes at the age of 81 years, with delayed and subnormal
photopic responses. The ERG recordings from WVU: III-8 (at
the age of 59 years with limited outer retinal atrophy) showed
moderate reduction of the scotopic bright flash response; and
subnormal photopic b-wave amplitude with normal peak
time, in addition to mild reduction of the EOG light rise (light
peak-dark trough ratio of 1.6) in both eyes. Because of the
putative role of RGR in the visual cycle,13 ERG was performed
in subject GC4177: V-2 after extended monocular dark
adaptation overnight. The amplitude of the scotopic mixed
bright flash response of the eye that underwent extended
dark adaptation was higher than that of the eye that
underwent standard dark adaptation for 20 minutes, but this
difference was not clinically significant.
DISCUSSION
We described the clinical features of retinal dystrophy
associated with a rare, heterozygous frameshifting mutation
in RGR in two families from the United States and the United
Kingdom with a haplotype that is shared with the first reported
family,8 and demonstrated the spectrum of retinal changes.
These ranged from seemingly innocuous reticular or diffuse
deep retinal pigment alteration, normal visual acuity, and
normal ERG, to diffuse atrophy of the retina and choroid with
severe visual loss. Longitudinal data for the asymptomatic
carriers were limited and, therefore, it is unknown if the retinal
changes in those subjects are nonprogressive signs of the
carrier state or represent an early stage of a slowly progressive
retinal dystrophy. The features of RGR-retinopathy emphasize
the importance of FAF imaging in recognizing mild retinal
manifestations and guiding the molecular investigation in
individuals with poor vision under dim lighting conditions
and peripapillary RPE atrophy. Variable expressivity (variable
phenotypic severity) and low penetrance (mutation carriers
with no associated phenotype) also have been observed in
pedigrees heterozygous for the p.Asp477Gly allele in RPE65,
another dominant disease affecting the RPE.13
In the first report of RGR retinopathy, the proband showed
bilaterally subnormal VA, macular atrophy, and severely
reduced ERGs, but the milder and early manifestations of this
retinopathy were not described.8 The clinical features of
retinal dystrophies with presumed primary RPE pathology
differ from those of retinitis pigmentosa by the paucity of
intraretinal bone spicule pigment deposition, and relative
preservation of the retinal vascular caliber. The phenotype
described in patients WVU: III-8 and GC4177: IV-1 resembles
FIGURE 2. Retinal images for the carriers of the c.836dupG mutation in RGR from the WVU pedigree. Color fundus photographs (A, D, G, J), FAF
(B, E, H, K), and OCT scans (C, F, I, L) for individuals from the WVU pedigree harboring the c.824dupG mutation in RGR, each column shows
images for one individual. (A–C) Images for patient III-8 showing: (A) diffuse chorioretinal atrophy, with partial preservation of the fovea (note the
lack of intraretinal pigment migration); (B) FAF of the posterior pole showing an island of preserved, yet mottled signal; (C) OCT shows loss of the
ellipsoid zone (EZ) in the entire scan except for a small area under the fovea, with marked attenuation of the outer nuclear layer (ONL); the
choroidal blood vessels are nearly absent. (D–F) images for patient III-6 showing: (D) extensive peripapillary atrophy, and an isolated patch of
intraretinal pigmentation (green arrow); (E) FAF shows loss of AF extending in the nasal retina, and a reticular pattern in the posterior pole with
foveal sparing; (F) OCT shows an intralaminar bridge (yellow arrow) demarcating the edge of the preserved outer retina; focal excrescence of the
RPE band is shown in the region of the reticular changes (cyan arrow). (G–I, J–L) Images for patients IV-5 and IV-6, showing peripapillary atrophy
and reticular pigmentation (G, J), peripapillary hypoautofluorescence and reticular changes nasal to the optic disc (H, K), sharp demarcation on
OCT between the atrophic and preserved retina (I, L, see cyan arrow in I).
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that observed in choroideremia (CHM), patients heterozygous
for the p.Asp477Gly mutation in RPE65, some PRPH2
mutations, and the p.M216K mutation in RHO.13–16 CHM,
and RPE65- and RGR-dominant retinopathies affect initially the
RPE due to the expression of their respective genes, and,
therefore, are likely to have similar clinical features. Early RPE
involvement in some cases of PRPH2-retinopathy and the
p.M216K mutation in RHO remain unexplained as both genes
are expressed in the photoreceptors.15,16 One early symptom
common to these disorders is reduced vision in the dark; it is
plausible to speculate that the impaired night vision is caused
by an abnormal visual cycle in the affected RPE while the cone
function is spared due to the Mu¨ller cell-mediated visual
cycle.17
Electrophysiologic testing in one individual with advanced
retinopathy showed loss of retinal function without shifting
the peak-time, suggesting that the main pathology in some
cases is loss of photoreceptor function without dysfunction.
The subnormal EOG in this patient can be associated with
reduction of the scotopic ERG and is milder than the reported
abolished EOG light rise in a patient with a similar retinal
phenotype in dominant RPE dystrophy due to the p.Asp477Gly
allele in RPE65.13 RGR and RPE65 are expressed in the RPE
and these alleles likely result in cellular toxicity.5,13,18 The
subnormal macular function, as shown on PERG in one
asymptomatic carrier, suggested that this retinopathy can
involve the macula.
To date, there are no other known disease-causing mutations
in RGR. It is informative to examine the population variants in
the gnomAD database (available in the public domain at http://
gnomad.broadinstitute.org/gene/ENSG00000148604; the Broad
Institute). The presence of numerous predicted loss of
function mutations suggests that haploinsufficiency is too
common to be responsible for retinal disease and supports our
hypothesis that the reported allele has a toxic or gain-of-
function effect. Moreover, eight instances of one specific final
exon frame-shifting mutation in 24028 African alleles also are
present (NM_002921.3:c.796_797insCC; p.Ile267Profs*37;
rs770085833). No other C-terminal frame-shifting alleles are
reported. The c.796_797insCC variant, unlike the c.836dupG
variant reported in our study, affects the noncanonical reading-
frame and produces a different carboxyl terminal peptide (by
an out-of-frame extension through the canonical stop codon,
adding seven novel amino-acids at the carboxyl terminal, and
replacing 29 amino-acids in the cytoplasmic domain of RGR).
In addition to containing distinct amino-acids, it also is shorter
than that predicted from the c.836dupG variant. This
observation further supported the assertion that the retinop-
athy reported here is due to toxicity conferred by the specific
abnormal carboxyl peptide.
The shared haplotype, in the three pedigrees, suggests that
the p.Ile280Asnfs*78 allele is a founder mutation. Recognition
of this phenotypic variability could lead to identification of
further affected families, and analysis of their respective
haplotypes.
FIGURE 3. Retinal images for the carriers of the c.836dupG mutation in RGR from the MEH pedigree. Color fundus photographs (A, D, G), FAF (B,
E, H), and OCT images (C, F, I) for individuals from the GC4177 family carrying the c.824dupG mutation in RGR. (A–C) Images for the proband IV-1
showing (A) diffuse chorioretinal atrophy, patches of intraretinal pigmentation (green arrows) are noted in the temporal retina; (B) FAF shows
diffuse loss of AF except for an island with scalloped edges temporal to the fovea; (C) OCT shows outer retinal tubulation (ORT; red arrow). (D–F)
Images for patient V-1. (D) Deep reticular pigmentation in the nasal retina. (E) FAF shows peripapillary atrophy and reticular changes in the nasal
retina, note the edge nasal to the fovea corresponding to the subtle irregularity of the ellipsoid zone and RPE bands on OCT ([F], cyan arrow). (G–I)
Fundus images for the asymptomatic carrier V-2 showing (G) peripapillary atrophy and reticular pigmentation nasal to the optic disc and temporal
to the macula. (H) Outer retinal atrophy extending toward the fovea (cyan arrow), and reticular AF pattern nasal to the disc. (I) OCT showing
attenuation of the ONL and EZ nasal to the fovea. Note the ORT temporal to optic nerve head. (J–L) fundus images of the asymptomatic carrier VI-1.
(J) peripapillary atrophy and diffuse deep retinal pigmentation anterior to the vascular arcades, better visualized on FAF (K). (L) OCT showing
absence of the ONL and EZ temporal to the optic nerve head; note also the ORT (cyan arrow).
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Our study reinforced the notion that, although candidate
gene testing—when a distinct phenotype is observed—often is
helpful, unbiased genetic screening using large NGS panels or
whole exome/genome sequencing can reveal unexpected
genotype–phenotype associations and expand the list of
candidate genes.19,20
In conclusion, this report exemplified the success of the
unbiased approaches of WGS and NGS in the molecular
diagnosis of a highly genetically heterogeneous disorder, such
as retinal dystrophy. The clinical features suggested a variable
severity of retinopathy consequent upon heterozygosity of a
specific allele of the RGR gene. The slow progression of this
retinopathy and possible primary involvement of the RPE
make this disorder tractable to potential therapeutic inter-
ventions.
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